Robert F. Kennedy Jr. has been a vocal critic of obesity drugs belonging to the fast-growing GLP-1 class.
Enthusiasm for Club holding Eli Lilly needs to be tempered — at least for now — as Wall Street grapples with the possibility of a major shakeup to health policy in Washington. The news Republican President-elect Donald Trump on Thursday nominated prominent vaccine skeptic and obesity-drug critic Robert F. Kennedy Jr. to lead the Department of Health and Human Services .
Ozempic is the posterchild of the fast-growing GLP-1 class, in which Novo Nordisk and Eli Lilly are currently the two dominant players. Some on Wall Street expect the market for GLP-1 drugs to be worth $100 billion by 2030. GLP-1s drugs mimic a gut hormone to help regulate blood sugar and suppress appetite, leading to weight loss. Eli Lilly's GLP-1 called tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, is at the heart of our investment thesis in the company.
Pharmaceuticals Pfizer Inc Moderna Inc Novo Nordisk A/S Novo Nordisk A/S LILLY DRN Breaking News: Markets Markets Investment Strategy Jim Cramer Stock Takes Spdr S&P Biotech Etf David A. Ricks John F. Kennedy Robert F. Kennedy Jr. GSK Plc GSK Plc Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Can Roche Holding Challenge Eli Lilly, Novo Nordisk in Weight Loss Market?Stocks Analysis by MarketBeat.com (Leo Miller) covering: Eli Lilly and Company, Novo Nordisk A/S, Roche Holding Ltd ADR. Read MarketBeat.com (Leo Miller)'s latest article on Investing.com
Read more »
Eli Lilly shares tumble as Q3 misses estimates, guidance loweredEli Lilly shares tumble as Q3 misses estimates, guidance lowered
Read more »
Eli Lilly stock tumbles 10% after missing estimates and slashing profit guidanceSkyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.
Read more »
Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidanceSkyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.
Read more »
Alphabet, Biogen, Humana rise premarket; AMD, Eli Lilly fallAlphabet, Biogen, Humana rise premarket; AMD, Eli Lilly fall
Read more »
Stocks making the biggest moves premarket: Eli Lilly, Caterpillar, VinFast, Alphabet and moreThese are the stocks posting the largest moves in premarket trading.
Read more »